Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
Real-time index price for S&P 500 ESG (ESG), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 7.5%. Looking ahead, revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared ...
Investor's Business Daily on MSN6d
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And RaiseGilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,878.72 today based on ...
Real-time index price for PHLX Housing Index (HGX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback